Akt1-IN-8 (Compound JL18) is a potent and oral bioavailable (41%) inhibitor of AKT1 kinase, with an IC50 of 8.8 nM. Akt1-IN-8 exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC50 of 3.0 µM. Akt1-IN-8 can reduce phosphorylated GSK3beta levels[1].
Molekulargewicht:
551.28
CAS Nummer:
[2247688-87-3]
Formel:
C21H25Br2N7O
Target-Kategorie:
Akt
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten